# Efficacy of Zoledronic Acid to Prevent Bone Loss Following Denosumab Discontinuation

> **NCT05405894** · — · UNKNOWN · sponsor: **University of Calgary** · enrollment: 20 (estimated)

## Conditions studied

- Osteoporosis
- Osteoporosis, Postmenopausal
- Osteopenia
- Bone Loss

## Interventions

- **DRUG:** Zoledronic acid

## Key facts

- **NCT ID:** NCT05405894
- **Lead sponsor:** University of Calgary
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-09-01
- **Primary completion:** 2024-07-01
- **Final completion:** 2025-07-01
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2024-05-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05405894

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05405894, "Efficacy of Zoledronic Acid to Prevent Bone Loss Following Denosumab Discontinuation". Retrieved via AI Analytics 2026-06-15 from https://api.ai-analytics.org/clinical/NCT05405894. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*